ATC code V: Various |
---|
|
Other ATC codes |
Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.
The main group of these compounds are the radiotracers used to diagnose dysfunction in body tissues. While not all medical isotopes are radioactive, radiopharmaceuticals are the oldest and remain the most common of such drugs.
As with other pharmaceutical drugs, there is standardization of the drug nomenclature for radiopharmaceuticals, although various standards coexist. The International Nonproprietary Names (INNs), United States Pharmacopeia (USP) names, and IUPAC names for these agents are usually similar other than trivial style differences. [1] The details are explained at Radiopharmacology § Drug nomenclature for radiopharmaceuticals .
A list of nuclear medicine radiopharmaceuticals follows. Some radioisotopes are used in ionic or inert form without attachment to a pharmaceutical; these are also included. There is a section for each radioisotope with a table of radiopharmaceuticals using that radioisotope. The sections are ordered alphabetically by the English name of the radioisotope. Sections for the same element are then ordered by atomic mass number.
47 Ca is a beta and gamma emitter.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Ca-47-Ca2+ | Bone metabolism | IV | In-vitro | Non-imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
C11-L-methyl-methionine | Brain tumour imaging Parathyroid imaging | IV | In-vivo | Imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
C14-Glycocholic acid | Breath test for small intestine bacterial overgrowth | Oral | In-vitro | Non-imaging |
C14-PABA (para-amino benzoic acid) | Pancreatic studies | Oral | In-vitro | Non-imaging |
C14-Urea | Breath test to detect Helicobacter pylori | Oral | In-vitro | Non-imaging |
C14-d-xylose | Breath test for small intestine bacterial overgrowth | Oral | In-vitro | Non-imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Cr51-[heart scan/blood volume | Red cell volume heart scan; sites of sequestration; gastrointestinal blood loss | IV | In-vitro | Non-imaging |
Cr51-Cr3+ | Gastrointestinal protein loss | IV | In-vitro | Non-imaging |
Cr51-EDTA (ethylenediaminetetraacetic acid) | Glomerular filtration rate measurement | IV | In-vitro | Non-imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Co57-Cyanocobalamin (vitamin B12) | Gastrointestinal absorption | Oral | In-vitro | Non-imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Co58-Cyanocobalamin (vitamin B12) | Gastrointestinal absorption | Oral | In-vitro | Non-imaging |
Name | Treatment of | Route of administration |
---|---|---|
Er169-Colloid | Arthritic conditions | Intra-articular |
18F is a positron emitter with a half-life of 109 minutes. It is produced in medical cyclotrons, usually from oxygen-18, and then chemically attached to a pharmaceutical formulation.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
F18-FDG (Fluorodeoxyglucose) | Tumor imaging Myocardial imaging | IV | In-vivo | Imaging |
F18-Sodium Fluoride | Bone imaging | IV | In-vivo | Imaging |
F18-Fluorocholine | Prostate tumor imaging | IV | In-vivo | Imaging |
F18-Desmethoxyfallypride | Dopamine receptor imaging | IV | In-vivo | Imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Ga67-Ga3+ | Tumor imaging | IV | In-vivo | Imaging |
Ga67-Ga3+ | Infection/inflammation imaging | IV | In-vivo | Imaging |
68Ga is a positron emitter, with a 68-minute half-life, produced by elution from germanium-68 in a gallium-68 generator or by proton irradiation of zinc-68.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Ga68-Dotatoc or Dotatate | Neuroendocrine tumor imaging | IV | In-vivo | Imaging |
Ga68-PSMA | Prostate cancer imaging | IV | In-vivo | Imaging |
3H or tritium is a beta emitter.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
H3-water | Total body water | Oral or IV | In-vitro | Non-imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
In111-DTPA (diethylenetriaminepenta-acetic acid) | Ventriculo-peritoneal shunt (LaVeen Shunt) | intraperitoneal injection | In-vivo | Imaging the radioactive substance |
In111-DTPA (diethylenetriaminepenta-acetic acid) | Cisternography | Intra-cisternal | In-vivo | Imaging |
In111-Leukocytes | Infection/inflammation imaging | IV | In-vivo | Imaging |
In111-Platelets | Thrombus imaging | IV | In-vivo | Imaging |
In111-Pentetreotide | Somatostatin receptor imaging | IV | In-vivo | Imaging |
In111-Octreotide | Somatostatin receptor imaging (Octreoscan) | IV | In-vivo | Imaging |
Iodine-123 (I-123) is a gamma emitter. It is used only diagnostically, as its radiation is penetrating and short-lived.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
I123-Iodide | Thyroid uptake | Oral or IV | In-vivo | Non-imaging |
I123-Iodide | Thyroid imaging Thyroid metastases imaging | Oral or IV | In-vivo | Imaging |
I123-o-Iodohippurate | Renal imaging | IV | In-vivo | Imaging |
I123-MIBG (m-iodobenzylguanidine) | Neuroectodermal tumour imaging | IV | In-vivo | Imaging |
I123-FP-CIT | SPECT imaging of Parkinson's Disease | IV | In-vivo | Imaging |
125I is a gamma emitter with a long half-life of 59.4 days (the longest of all radioiodines used in medicine). Iodine-123 is preferred for imaging, so I-125 is used diagnostically only when the test requires a longer period to prepare the radiopharmaceutical and trace it, such as a fibrinogen scan to diagnose clotting. I-125's gamma radiation is of medium penetration, making it more useful as a therapeutic isotope for brachytherapy implant of radioisotope capsules for local treatment of cancers.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
I125-fibrinogen | Clot imaging | IV | In-vivo | Imaging |
131I is a beta and gamma emitter. It is used both to destroy thyroid and thyroid cancer tissues (via beta radiation, which is short-range), and also other neuroendocrine tissues when used in MIBG. It can also be seen by a gamma camera, and can serve as a diagnostic imaging tracer, when treatment is also being attempted at the same time. However iodine-123 is usually preferred when only imaging is desired.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
I131-Iodide | Thyroid uptake | Oral | In-vivo | Non-imaging |
I131-Iodide | Thyroid metastases imaging | Oral or IV | In-vivo | Imaging |
I131-MIBG (m-iodobenzylguanidine) | Neuroectodermal tumor imaging | IV | In-vivo | Imaging |
Name | Treatment of | Route of administration |
---|---|---|
I131-Iodide | Thyrotoxicosis | IV or Oral |
I131-Iodide | Non-toxic goiter | IV or Oral |
I131-Iodide | Thyroid carcinoma | IV or Oral |
I131-MIBG (m-iodobenzylguanidine) | Malignant disease | IV |
59Fe is a beta and gamma emitter.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Fe59-Fe2+ or Fe3+ | Iron metabolism | IV | In-vitro | Non-imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging the radioactive substance |
---|---|---|---|---|
Kr81m-Gas | Lung ventilation imaging | Inhalation | In-vivo | Imaging |
Kr-81m-Aqueous solution | Lung perfusion imaging | IV | In-vivo | Imaging |
Name | Treatment of | Route of administration | In-vitro / in-vivo |
---|---|---|---|
177Lu-DOTA-TATE | gastroenteropancreatic neuroendocrine tumors (GEP-NETs) | IV | In-vivo |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
N13-Ammonia | Myocardial blood flow imaging | IV | In-vivo | Imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
O15-Water | Cerebral blood flow imaging Myocardial blood flow imaging | IV bolus | In-vivo | Imaging |
Name | Treatment of | Route of administration |
---|---|---|
P32-Phosphate | Polycythemia and related disorders | IV or Oral |
Name | Treatment of | Route of administration |
---|---|---|
Ra223 cation (223RaCl2) | metastatic cancer in bone | IV |
82Rb is a positron and gamma emitter.
Name | Investigation of | Route of administration |
---|---|---|
Rb-82 chloride | Myocardial Imaging | IV |
153Sm is a beta and gamma emitter.
Name | Treatment of | Route of administration |
---|---|---|
Sm153-EDTMP (Ethylenediaminotetramethylenephosphoric acid) | Bone metastases | IV |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Se75-Selenorcholesterol | Adrenal gland imaging | IV | In-vivo | Imaging |
Se75-SeHCAT (23-Seleno-25-homo-tauro-cholate) | Bile salt absorption | Oral | In-vivo | Imaging |
22Na is a positron and gamma emitter.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Na22-Na+ | Electrolyte studies | Oral or IV | In-vitro | Non-imaging |
24Na is a beta and gamma emitter.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Na24-Na+ | Electrolyte studies | Oral or IV | In-vitro | Non-imaging |
Name | Treatment of | Route of administration |
---|---|---|
Sr89-Chloride | Bone metastases | IV |
Technetium-99m is a gamma emitter. It is obtained on-site at the imaging center as the soluble pertechnetate which is eluted from a technetium-99m generator, and then either used directly as this soluble salt, or else used to synthesize a number of technetium-99m-based radiopharmaceuticals.
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Tc99m-pertechnetate | Thyroid uptake and thyroid imaging Stomach and salivary gland imaging | IV | In-vivo | Imaging |
Tc99m-pertechnetate | Lacrimal imaging | Eye drops | In-vivo | Imaging |
Tc99m-Human albumin | Cardiac blood pool imaging | IV | In-vivo | Imaging |
Tc99m-Human albumin | Peripheral vascular imaging | IV | In-vivo | Imaging |
Tc99m-Human albumin macroaggregates or microspheres | Lung perfusion imaging | IV | In-vivo | Imaging |
Tc99m-Human albumin macroaggregates or microspheres | Lung perfusion imaging with venography | IV | In-vivo | Imaging |
Tc99m-Phosphonates and phosphates (MDP/HDP) | Bone imaging | IV | In-vivo | Imaging |
Tc99m-Phosphonates and phosphates | Myocardial imaging | IV | In-vivo | Imaging |
Tc99m-DTPA (diethylenetriaminepenta-acetic acid) | Renal imaging First pass blood flow studies Brain imaging | IV | In-vivo | Imaging |
Tc99m-DTPA (diethylenetriaminepenta-acetic acid) | Lung ventilation imaging | Aerosol inhalation | In-vivo | Imaging |
Tc99m-DMSA(V) (dimercaptosuccinic acid) | Tumor imaging | IV | In-vivo | Imaging |
Tc99m-DMSA(III) (dimercaptosuccinic acid) | Renal imaging | IV | In-vivo | Imaging |
Tc99m-Colloid | Bone marrow imaging GI Bleeding | IV | In-vivo | Imaging |
Tc99m-Colloid | Lymph node imaging | Interstitial | In-vivo | Imaging |
Tc99m-Colloid | Esophageal transit and reflux imaging Gastric emptying imaging | Oral | In-vivo | Imaging |
Tc99m-Colloid | Lacrimal imaging | Eye drops | In-vivo | Imaging |
Tc99m-HIDA (Hepatic iminodiacetic acid) | Functional biliary system imaging | IV | In-vivo | Imaging |
Tc99m-Denatured (heat damaged) red blood cells | Red cell volume Spleen imaging | IV | In-vitro | Non-imaging |
Tc99m-Whole red blood cells | GI bleeding Cardiac blood pool imaging | IV | In-vivo | Imaging |
Tc99m-MAG3 (mercaptoacetyltriglycine) | Renal imaging First pass blood flow imaging | IV | In-vivo | Imaging |
Tc99m-Exametazime (HMPAO) | Cerebral blood flow imaging | IV | In-vivo | Imaging |
Tc99m-Exametazime labelled leucocytes | Infection/inflammation imaging | IV | In-vivo | Imaging |
Tc99m-Sestamibi (MIBI - methoxy isobutyl isonitrile) | Parathyroid imaging Non-specific tumor imaging | IV | In-vivo | Imaging |
Tc99m-Sulesomab (IMMU-MN3 murine Fab'-SH antigranulocyte monoclonal antibody fragments) | Infection/inflammation imaging | IV | In-vivo | Imaging |
Tc99m-Technegas | Lung ventilation imaging | Inhalation | In-vivo | Imaging |
Tc99m-Human immunoglobulin | Infection/inflammation imaging | IV | In-vivo | Imaging |
Tc99m-Tetrofosmin | Parathyroid imaging Myocardial imaging | IV | In-vivo | Imaging |
Tc99m-ECD (ethyl cysteinate dimer) | Brain imaging----- | IV | In-vivo | Imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Tl201-Tl+ | Non-specific tumor imaging Thyroid tumor imaging | IV | In-vivo | Imaging |
Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
---|---|---|---|---|
Xe133-gas | Lung ventilation studies | Inhalation | In-vivo | Imaging |
Xe133 in isotonic sodium chloride solution | Cerebral blood flow | IV | In-vivo | Imaging |
Name | Treatment of | Route of administration |
---|---|---|
Y90-Silicate | Arthritic conditions | Intra-articular |
Y90-Silicate | Malignant disease | Intracavitary |
Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body.
A synthetic radioisotope is a radionuclide that is not found in nature: no natural process or mechanism exists which produces it, or it is so unstable that it decays away in a very short period of time. Examples include technetium-95 and promethium-146. Many of these are found in, and harvested from, spent nuclear fuel assemblies. Some must be manufactured in particle accelerators.
Radionuclide therapy uses radioactive substances called radiopharmaceuticals to treat medical conditions, particularly cancer. These are introduced into the body by various means and localise to specific locations, organs or tissues depending on their properties and administration routes. This includes anything from a simple compound such as sodium iodide that locates to the thyroid via trapping the iodide ion, to complex biopharmaceuticals such as recombinant antibodies which are attached to radionuclides and seek out specific antigens on cell surfaces.
Single-photon emission computed tomography is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera, but is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
Nuclear medicine or nucleology is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear imaging, in a sense, is "radiology done inside out" because it records radiation emitted from within the body rather than radiation that is transmitted through the body from external sources like X-ray generators. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.
A radioactive tracer, radiotracer, or radioactive label is a chemical compound in which one or more atoms have been replaced by a radionuclide so by virtue of its radioactive decay it can be used to explore the mechanism of chemical reactions by tracing the path that the radioisotope follows from reactants to products. Radiolabeling or radiotracing is thus the radioactive form of isotopic labeling. In biological contexts, use of radioisotope tracers are sometimes called radioisotope feeding experiments.
Scintigraphy, also known as a gamma scan, is a diagnostic test in nuclear medicine, where radioisotopes attached to drugs that travel to a specific organ or tissue (radiopharmaceuticals) are taken internally and the emitted gamma radiation is captured by gamma cameras, which are external detectors that form two-dimensional images in a process similar to the capture of x-ray images. In contrast, SPECT and positron emission tomography (PET) form 3-dimensional images and are therefore classified as separate techniques from scintigraphy, although they also use gamma cameras to detect internal radiation. Scintigraphy is unlike a diagnostic X-ray where external radiation is passed through the body to form an image.
Radiopharmacology is radiochemistry applied to medicine and thus the pharmacology of radiopharmaceuticals. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide. In the book Technetium a total of 31 different radiopharmaceuticals based on Tc-99m are listed for imaging and functional studies of the brain, myocardium, thyroid, lungs, liver, gallbladder, kidneys, skeleton, blood and tumors.
A technetium-99m generator, or colloquially a technetium cow or moly cow, is a device used to extract the metastable isotope 99mTc of technetium from a decaying sample of molybdenum-99. 99Mo has a half-life of 66 hours and can be easily transported over long distances to hospitals where its decay product technetium-99m is extracted and used for a variety of nuclear medicine diagnostic procedures, where its short half-life is very useful.
Iodine-131 is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. It also plays a major role as a radioactive isotope present in nuclear fission products, and was a significant contributor to the health hazards from open-air atomic bomb testing in the 1950s, and from the Chernobyl disaster, as well as being a large fraction of the contamination hazard in the first weeks in the Fukushima nuclear crisis. This is because 131I is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission. See fission product yield for a comparison with other radioactive fission products. 131I is also a major fission product of uranium-233, produced from thorium.
The pertechnetate ion is an oxyanion with the chemical formula TcO−
4. It is often used as a convenient water-soluble source of isotopes of the radioactive element technetium (Tc). In particular it is used to carry the 99mTc isotope which is commonly used in nuclear medicine in several nuclear scanning procedures.
There are 37 known isotopes of iodine (53I) from 108I to 144I; all undergo radioactive decay except 127I, which is stable. Iodine is thus a monoisotopic element.
Sodium pertechnetate is the inorganic compound with the formula NaTcO4. This colourless salt contains the pertechnetate anion, TcO−
4 that has slightly distorted tetrahedron symmetry both at 296 K and at 100 K while the coordination polyhedron of the sodium cation is different from typical for scheelite structure. The radioactive 99m
Tc
O−
4 anion is an important radiopharmaceutical for diagnostic use. The advantages to 99m
Tc
include its short half-life of 6 hours and the low radiation exposure to the patient, which allow a patient to be injected with activities of more than 30 millicuries. Na[99m
Tc
O
4] is a precursor to a variety of derivatives that are used to image different parts of the body.
Iodine-125 (125I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.
Iodine-123 (123I) is a radioactive isotope of iodine used in nuclear medicine imaging, including single-photon emission computed tomography (SPECT) or SPECT/CT exams. The isotope's half-life is 13.2230 hours; the decay by electron capture to tellurium-123 emits gamma radiation with a predominant energy of 159 keV. In medical applications, the radiation is detected by a gamma camera. The isotope is typically applied as iodide-123, the anionic form.
Radioactivity is generally used in life sciences for highly sensitive and direct measurements of biological phenomena, and for visualizing the location of biomolecules radiolabelled with a radioisotope.
Technetium-99m (99mTc) is a metastable nuclear isomer of technetium-99, symbolized as 99mTc, that is used in tens of millions of medical diagnostic procedures annually, making it the most commonly used medical radioisotope in the world.
Nuclear medicine physicians, also called nuclear radiologists or simply nucleologists, are medical specialists that use tracers, usually radiopharmaceuticals, for diagnosis and therapy. Nuclear medicine procedures are the major clinical applications of molecular imaging and molecular therapy. In the United States, nuclear medicine physicians are certified by the American Board of Nuclear Medicine and the American Osteopathic Board of Nuclear Medicine.
Gallium (68Ga) gozetotide or Gallium (68Ga) PSMA-11 sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68Ga conjugated to prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx)-HBED-CC, used for imaging prostate cancer by positron emission tomography (PET). The PSMA targeting ligand specifically directs the radiolabeled imaging agent towards the prostate cancerous lesions in men.
Theranostics, also known as theragnostics, is an emerging field in precision medicine that combines diagnostic and therapeutic approaches to provide the potential for personalized treatment and real-time monitoring of the effectiveness of treatments. Improvements in imaging techniques and targeted therapies are the basis of the field of theranostics. When medical imaging is coupled with the development of novel radiotracers and contrast agents, theranostics may provide opportunities for precise diagnosis and targeted therapy.